Treatment of retinopathy of prematurity by targeting AMP-dependent kinase

• Project/Area Number: 15K20263
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Ophthalmology
• Research Institution: Okayama University
• Principal Investigator: Hosokawa Mio 岡山大学, 大学病院, 助教 (00711053)
• Research Collaborator: SHIRAGA Fumio ; MORIZANE Yuki ; SHIODE Yusuke
• Project Period (FY): 2015-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000); Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
• Keywords: 未熟児網膜症

Outline of Final Research Achievements

In this study, we clarified the influence of retinopathy of prematurity on the survival and protein expression of cells constituting the retina and investigated the possibility of application of AMP - dependent kinase for treatment. As a result, it was suggested that changes in oxygen concentration and oxidative stress changed ion transport in retinal pigment epithelial cells and extracellular matrix resolution capability, and are involved in the pathology of retinopathy of prematurity. In addition, these changes were inhibited by AMP-dependent kinase. Further investigation is needed on the possibility of therapeutic application of AMP-dependent kinase for prematurity retinopathy in the future.